SCOTUS Closes the Warning-Label Door on Glyphosate Claims
The most consequential mass-tort ruling since the Wyeth v. Levine preemption line arrived June 25, 2026, when the U.S. Supreme Court handed down a 7-2 decision in Monsanto v. Durnell, No. 24-1068. Justice Kavanaugh's majority opinion holds that the Federal Insecticide, Fungicide, and Rodenticide Act expressly preempts any state-law claim requiring a cancer warning on Roundup's glyphosate label, because EPA has continuously approved that label without such a warning since 1974. Missouri plaintiff John Durnell had secured a jury award at the state level; the Court reversed and remanded.
The practical effect is immediate and severe for the plaintiff side of glyphosate mass tort. More than 60,000 cases remain pending, the vast majority built on a failure-to-warn theory that Durnell now eliminates. Bayer enters the July 9 final-approval hearing in the Circuit Court of the City of St. Louis holding its $7.25B class settlement (which received preliminary approval March 4, 2026) with the leverage a defendant acquires only when the plaintiffs' primary liability theory has been cut by the country's highest court. The attorney fee request embedded in that settlement stands at $675 million, payable to negotiating counsel.
Justices Jackson and Sotomayor dissented. Their core argument, that EPA label approval operates as a regulatory floor rather than a federal preemption ceiling, preserves an avenue for future legislative challenge but does not alter current litigation strategy. The opt-out deadline was June 4, meaning plaintiffs who remained in the class are now positioned for settlement distributions rather than independent litigation on a theory foreclosed at the federal level.
The ruling also frames a question the bar has not fully answered: which other defendants in pesticide and herbicide personal-injury dockets hold equivalent FIFRA preemption arguments, and whether the Durnell logic extends to analogous federal labeling regimes such as the Federal Hazardous Substances Act.
Firms carrying open glyphosate files should audit each case against the Durnell preemption standard before the July 9 St. Louis hearing, particularly where failure-to-warn is the sole surviving theory.
Morgan and Morgan's $1B-Plus MSO Exploration Resets PI Firm Capital Benchmarks
On June 5, 2026, founder John Morgan confirmed that Morgan and Morgan, the largest U.S. plaintiff PI firm by estimated annual revenue of over $2 billion, has engaged JPMorgan to evaluate a minority stake sale targeting more than $1 billion. The proposed vehicle is a Management Services Organization that separates marketing, intake technology, care coordination, and back-office operations from the legal practice itself. The MSO portion accepts outside capital without implicating lawyer-independence rules; the legal entity remains attorney-owned.
The deal, if completed, would represent the highest-profile private-equity entry into the plaintiff bar on record. John Morgan has publicly discussed an eventual IPO, which would be the first for a major U.S. plaintiffs firm. Samson Partners, the investment bank tracking PI-sector transactions, currently counts 20 PI MSO deals in parallel stages of negotiation or closing, confirming that Morgan and Morgan's move is the headline transaction within a broader capital-formation shift rather than an isolated event.
What institutional capital is purchasing, structurally, is the non-legal infrastructure: intake conversion systems, AI-assisted triage, lien management platforms, care-coordination networks, and brand distribution. Those assets carry recurring-revenue characteristics that support conventional valuation multiples. The contingency fee generated by the legal work stays behind ethics walls. The competitive implication for mid-size plaintiff firms is that any operation without a documented intake tech stack and a defensible lien management workflow is now measured against capitalized platforms rather than comparable-size firms.
With 20 PI MSO deals reportedly in progress nationwide and the largest plaintiff firm in the country exploring a $1B-plus PI firm MSO capital transaction, this structure has become the benchmark against which every mid-size practice will now be evaluated by both lateral talent and referring co-counsel.
Nuclear Med-Mal Verdicts Define the Institutional-Defendant Settlement Floor
Two med-mal verdicts this year anchor the 52% increase in awards above $10 million recorded from 2023 to 2024. On June 18, 2026, an Aroostook County Superior Court jury in Maine returned a $23.1M verdict against Northern Light AR Gould Hospital and its parent, Northern Light Health, in Giordano v. Northern Light AR Gould Hospital. Plaintiff Robert Giordano suffered permanent paralysis after the defendants allegedly failed to identify and respond to clinical signs of spinal cord compression. The award is the largest non-death med-mal verdict in Maine history and the largest med-mal verdict of any category north of Portland.
The Philadelphia figure for context: in [Minor plaintiff] v. Jefferson Health / Einstein Medical Center Philadelphia, decided March 20, 2026 in the Philadelphia Court of Common Pleas, a jury awarded $108.6 million, structured as $1.4M pain and suffering, $1M in lost earning capacity, and $106.1M in future medical and life-care expenses projected over a 68-year expected additional lifespan. The underlying claim involved a 2018 delivery in which forceps use was alleged to be undocumented, causing permanent cognitive and intellectual brain damage. That award is the largest Philadelphia med-mal verdict since the $183M Penn Medicine birth-injury judgment in 2023.
Both cases share the structural profile that plaintiff med-mal counsel should map: institutional defendants with documented process failures, life-care plans anchored to actuarial longevity projections, and jury willingness to assign the full present-value cost of long-duration care. For medical providers serving PI and med-mal plaintiffs, these verdicts signal that future-care damage calculations are being recalibrated upward; lien valuations tied to pre-trial estimates may not reflect the settlement floor that a post-verdict institutional defendant now faces.
The Maine and Philadelphia verdicts confirm that institutional hospital defendants with documented failure-to-act claims and life-care plan support are generating nine-figure exposure regardless of geographic market size, a dynamic that should inform both case selection criteria and lien negotiation strategy for treating providers.
New York's 25% Funding Cap Takes Effect as Three States Watch for Replication
The New York Consumer Litigation Funding Act took effect June 17, 2026, establishing the first major-state statutory cap on pre-settlement funder recovery: 25% of gross proceeds. The Act mandates plain-language contracts, grants plaintiffs a 10-day right of rescission, and prohibits funders from influencing litigation strategy, settlement decisions, or attorney-client communications. Funders operating in New York must register with the New York Department of Financial Services by February 13, 2027.
Georgia, Florida, and Texas are each tracking the statute as a potential replication model. If any of those three states adopts a comparable cap, the geographic reach of the restriction will cover a substantial portion of the nation's plaintiff PI caseload by raw case count.
The operational effect is not limited to funders. Medical providers who structured lien portfolios assuming that plaintiffs would have access to high-multiple pre-settlement advances will find that clients' ability to sustain treatment over long case cycles is constrained by the new ceiling. For lien-based imaging centers, pain management practices, and surgical facilities, this is a working-capital planning variable affecting active portfolios. Where pre-settlement advances previously provided broader case-duration financing, the 25% cap on gross proceeds limits total advance capacity relative to anticipated recovery, a compression that hits hardest in high-cost, slow-moving soft-tissue and spine cases where treatment typically outpaces early carrier offers.
Medical providers with active lien portfolios in New York should model the 25% gross-proceeds cap against current client funding levels, because constrained plaintiff liquidity has historically correlated with earlier settlement pressure and reduced lien resolution amounts at closing.
EvenUp PLaaS and the Industrialization of Pre-Litigation Workflow
EvenUp, valued at approximately $2 billion as of late 2025, launched its PLaaS offering on May 13-14, 2026. The model pairs purpose-built AI with U.S.-based case managers to handle the full pre-litigation sequence: intake, care coordination, records retrieval, demand preparation, carrier settlement negotiation, and an optional lien resolution module. Early adopter data published through BusinessWire shows records arriving 66 days faster than firm-managed timelines, demands issued 47 days faster, and carrying-cost savings of $1,000 per case. The platform has generated more than $10 million in subscriptions from firms in early testing, with early adopters recovering approximately 95% of available third-party policy limits.
The lien resolution module is the detail medical providers need to track closely. EvenUp does not practice law, but the optional lien component means an AI-driven platform with pre-set reduction parameters is the first point of contact for lien discussions in cases processed through PLaaS. Providers who have historically negotiated reductions directly with plaintiff counsel, or who have relied on the attorney relationship as a soft governor of lien treatment, are now operating in a workflow where the initial reduction request arrives from an automated system before any attorney contact occurs.
Separately, the April 16, 2026 integration of Supio's PI case-intelligence dashboard with Thomson Reuters Westlaw Advantage places AI jurisdictional surveys and litigation document analysis directly inside the case-management layer. Supio has handled over 27,000 PI cases and more than $1 billion in settlements. The platform scans medical records to surface missed injuries, a function with direct lien completeness implications: where an injury is identified after the demand has issued, lien holders excluded from the original demand package face a materially harder reduction negotiation.
Medical providers generating liens in cases processed through PLaaS or Supio-integrated workflows should establish direct communication protocols with referring firms before the demand stage, since AI-driven platforms are compressing the records-to-demand window in ways that can exclude lien holders from the primary negotiation cycle.
The 60,000-plus glyphosate opt-in claimants who did not exit before the June 4 deadline will receive their first clear picture of per-claimant distribution when the July 9 St. Louis hearing concludes, and whether the $675M negotiating-counsel fee request survives judicial scrutiny is the unanswered calculation that will determine how much of Bayer's $7.25B actually reaches the plaintiff class.